NeuroMetrix Launches Website for SENSUS™ Pain Management System
WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 30, 2013--
NeuroMetrix, Inc. (Nasdaq: NURO),
www.neurometrix.com,
a medical device company focused on the diagnosis and treatment of the
neurological complications of diabetes, announced that is has launched a
website (
www.neurometrix.com/sensus)
for the SENSUS Pain Management System. The website provides patients,
physicians and durable medical equipment (DME) suppliers with a one-stop
Internet portal for SENSUS information and support material.
SENSUS is a transcutaneous electrical nerve stimulator intended for the
symptomatic relief and management of chronic intractable pain in the
lower legs and feet. It offers physicians and their patients advanced
medical technology in a light weight, low profile device worn on the
upper calf that is activated by the press of a single button. The
Company’s marketing efforts for SENSUS are targeted at patients with
diabetes who suffer from chronic pain, most commonly due to painful
diabetic neuropathy. It is partnering with a growing network of DME
suppliers responsible for physician detailing, supplying product to
patients, and insurance billing.
“The SENSUS website provides convenient, comprehensive product support,”
said Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer
of NeuroMetrix. “Since we launched SENSUS several weeks ago we have been
encouraged by the interest we’ve seen from physicians and patients. This
new website is a tool to reach a growing audience. It contains a wide
range of product and disease information that we intend to expand over
time.”
About NeuroMetrix
NeuroMetrix is an innovative medical device company that develops and
markets home use and point-of-care devices for the treatment and
management of diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot
ulcers that may require amputation, cause disabling chronic pain, and
increase the risk of falling in the elderly. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company’s products are used by physicians and managed care organizations
to optimize patient care and reduce healthcare costs. The company
markets the NC-stat® DPNCheck™ device, which
is a rapid, accurate, and quantitative point-of-care test for diabetic
neuropathy. This product is used to detect diabetic neuropathy at an
early stage and to guide treatment. The company also markets the SENSUS™
Pain Management System for treating chronic pain, focusing on physicians
managing patients with painful diabetic neuropathy. The company has
additional therapeutic products in its pipeline. For more information,
please visit http://www.neurometrix.com.
Source: NeuroMetrix, Inc.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
